Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is... Read more »
Section 32, which invests in healthcare and life sciences companies with a technology component, has added a third managing partner.
The small venture capital firm was started in San Diego about... Read more »
Dauntless Pharmaceuticals formed in 2016, and its founders said the Sofinnova Ventures-backed firm planned to take a new approach to building biotechs.
Instead of advancing a broad stable of early-stage drug... Read more »
Red blood cells need iron to carry oxygen from the lungs to the rest of the body, and having too little or too much can lead to serious health problems.
When... Read more »
Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition in the... Read more »
Earlier this year, it seemed that companies testing Alzheimer’s disease treatments based on a long-held hypothesis as to its cause—brain deposits of a protein called beta amyloid—were giving up the ghost.... Read more »
Six months after Biogen stopped work on a closely watched experimental Alzheimer’s disease treatment, the neuroscience drug developer is reviving it with plans to file for FDA approval.
Aducanumab’s Phase 3... Read more »
The FDA on Monday approved a Vertex Pharmaceuticals cystic fibrosis treatment that combines three drugs, a decision that comes three months after the company submitted its application and five months before... Read more »
An experimental breast cancer drug from Seattle Genetics is headed for FDA review after the company reported a pivotal clinical trial met its main goals.
The company has been testing tucatinib... Read more »
Even as researchers discover more links between specific proteins and human disease, it’s still hard to find small molecules or antibodies that can bind to those drug targets.
San Diego biotech... Read more »
Glenmark Pharmaceuticals, which has made generic drugs for about four decades, on Tuesday formally spun off its drug R&D unit as an independent business aiming to advance a handful of novel... Read more »
The number of investments that venture capitalists will make this year in pharmaceutical and biotech companies is on pace to match last year’s record—and that money continues to shift into earlier-stage... Read more »
[Updated 7:21 p.m. 10/11. See below.] Scientists, no matter how sexy the research they’re conducting, aren’t immune from the administrative minutiae of office life.
Such tasks steal time away... Read more »
This summer Nestlé Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD.
About a... Read more »
Following the late-stage failure of its lead program, an experimental gene therapy treatment for the most aggressive form of brain cancer, Tocagen will reduce its workforce by 65 percent, the company... Read more »
Biologists have been using artificially created DNA, produced through what’s known as chemical DNA synthesis, as a research tool for decades.
Now, as demand for engineered DNA rises, a handful of... Read more »
No one would argue that San Diego is overflowing with venture capitalists in the way, say, the San Francisco Bay Area is. In fact, the region’s relative dearth of investors is... Read more »
[Updated 2:40 p.m. 9/27. See below.] Zingle, a startup whose software is used by hospitality, travel, and retail industries to more easily and quickly connect with their customers via... Read more »
While the headlines may be dominated by news of WeWork putting its IPO on hold after reports about its questionable corporate governance, the overall initial public offering market is doing just... Read more »
Under Bob Sullivan, the Rady School of Management at UC San Diego matured into its teenage years. Sullivan became Rady’s founding dean in 2003, ahead of the fall 2004 enrollment of... Read more »